NCT07493096 Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders
| NCT ID | NCT07493096 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Healing Hope International |
| Condition | Neurodevelopmental Disorders |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-03-01 |
| Primary Completion | 2028-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2026-03-01 with a primary completion date of 2028-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This observational study evaluates functional and developmental outcomes in pediatric participants undergoing a two week intensive multimodal neurorehabilitation program. The program is designed for children with neurodevelopmental disorders, including but not limited to cerebral palsy, autism spectrum disorder, developmental delay, hypoxic ischemic encephalopathy (HIE), and chromosomal or genetic abnormalities. Participants receive individualized therapy sessions for approximately 2.5 hours per day over a two week period. The intervention is not standardized but is tailored to each child's specific needs and may include components such as sensory integration, motor planning, reflex integration, oculomotor training, executive functioning activities, communication support, and other brain based therapeutic approaches. The purpose of this study is to observe changes in functional abilities, including attention, motor coordination, emotional regulation, communication, and activities of daily living. Outcomes are assessed using clinician observation and parent reported changes before and after the intensive program, with limited follow-up when available. This study does not assign participants to a specific treatment as part of a research protocol. Instead, it collects real world data from children already participating in a clinical therapy program to better understand potential benefits of intensive, individualized neurorehabilitation approaches.
Eligibility Criteria
Inclusion Criteria: * Pediatric participants between approximately 4 and 12 years of age at the time of enrollment. * Diagnosed with or presenting with neurodevelopmental, neurologic, or genetic conditions, including but not limited to: * cerebral palsy * autism spectrum disorder * developmental delay * hypoxic ischemic encephalopathy (HIE) * traumatic brain injury * sensory processing disorder * chromosomal or genetic abnormalities * Demonstrate functional impairments in one or more neurodevelopmental domains, including: * motor coordination or motor planning * sensory processing * attention or executive functioning * oculomotor or visual processing * communication * emotional or behavioral regulation * activities of daily living * Enrolled in and able to participate in a two-week intensive therapy program consisting of approximately 2.5 hours per day/ 5 days per week * Able to complete baseline and post-program clinical assessment using clinician-observed or caregiver-reported measures. * Parent or legal guardian able to provide informed consent and participate in reporting functional outcomes when applicable. Exclusion Criteria: * Medical instability or acute medical condition that would prevent safe participation in an intensive therapy program. * Severe uncontrolled seizure activity or other neurologic condition that would interfere with participation in structured therapeutic activities, as determined by the treating clinician. * Behavioral or psychological conditions that would prevent safe engagement in the therapy environment despite appropriate support. * Inability to attend or complete the full two-week intensive program. * Lack of sufficient baseline or post-intervention data to assess change in functional performance. * Concurrent participation in another structured intervention or clinical study that would confound interpretation of functional outcomes, at the discretion of the investigator.
Contact & Investigator
Dr. Tina Casoglos-Adamopoulos, OT, OTD, BCP
PRINCIPAL INVESTIGATOR
Board Certified Pediatric Therapist Executive Director Ability and Beyond Integrated Therapies
Frequently Asked Questions
Who can join the NCT07493096 clinical trial?
This trial is open to participants of all sexes, aged 4 Years or older, up to 12 Years, studying Neurodevelopmental Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07493096 currently recruiting?
Yes, NCT07493096 is actively recruiting participants. Contact the research team at genelle@abilityandbeyond.com for enrollment information.
Where is the NCT07493096 trial being conducted?
This trial is being conducted at The Woodlands, United States.
Who is sponsoring the NCT07493096 clinical trial?
NCT07493096 is sponsored by Healing Hope International. The principal investigator is Dr. Tina Casoglos-Adamopoulos, OT, OTD, BCP at Board Certified Pediatric Therapist Executive Director Ability and Beyond Integrated Therapies. The trial plans to enroll 100 participants.